PBS Pacgen Life Science Corporation

Pacgen Life Science Corporation ("Pacgen" or the "Company") (TSX VENTURE:PBS)
announced today that Pacgen Inc., the Company's wholly owned subsidiary based in
Irvine, California USA, has signed an exclusive distribution agreement with
Arise Biotech Corporation ("Arise") to distribute Arise's automated pipetting
systems and electronic pipettes in the United States.


"We have selected Arise's automated micro-liquid handling technologies and
digital pipettes products for distribution in the US market and have already
installed their systems in our customer laboratories," said Dr. Ming S. Liu,
Chief Executive Officer of Pacgen. "Pacgen has undertaken a number of business
initiatives and plans to continue strengthening its bio-products portfolio for
distribution," added Dr. Liu.


About Pacgen

Pacgen is a life science technology company focused on the commercialization of
biomedical products and services, including its previous development of novel
therapeutic drug candidates. The Company is currently looking to facilitate its
corporate transformation from a bio-pharma R&D business into a
revenue-generating company. For additional information, please visit
www.pacgenlife.com.


About Arise Biotech Corporation

Arise Biotech Corporation is a customer-oriented, innovative company established
in Taipei, Taiwan in 2002. Arise designs, manufactures, and markets liquid
handling products, such as electronic pipettes, electronic pipette aids and
tips, etc. under its own brand name and OEM/ODM partners' brand names. Our goal
is to bring comfort, accuracy and convenience to our customers, so they can
efficiently conduct their experiments and enjoy their research process at the
same time. For additional information, please visit www.arisebio.com.tw.


Forward looking Statements

Certain statements included in this press release may be considered
forward-looking. Statements relating to, among other things, anticipated
financial performance, business prospects, strategies, regulatory developments,
market acceptance and future commitments constitute forward-looking statements.
All forward-looking statements are based on Pacgen's current beliefs and
expectations as well as assumptions relating to the successful completion of its
clinical trials and pre-clinical studies, the time and process required to
obtain regulatory approval for commercialization of its product, the ability of
Pacgen to raise additional capital in future on favourable terms, the impact of
competitive products and pricing in the market, new product development, and the
successful and timely completion of corporate collaborations or licensing
arrangements for its research programs. Such statements involve known and
unknown risks, uncertainties and other factors that may cause actual results,
level of activity, performance or achievements to be materially different from
those implied by such statements, and therefore these statements should not be
read as guarantees of future performance or results. Such factors include, among
others, our stage of development, lack of product revenues, additional capital
requirements, risk associated with completion of clinical trials and obtaining
regulatory approval, dependence on collaborative partners, and our ability to
protect our intellectual property.


Wherever possible, words such as "anticipate", "believe", "expect", "may",
"could", "will", "potential", "intend", "estimate", "should", "plan", "predict",
"project" or the negative or other variations of such expressions reflect
Pacgen's current beliefs and assumptions and are based on the information
currently available to Pacgen. Certain risks and uncertainties, including those
risk factors identified by Pacgen in its annual management's discussion and
analysis dated July 29, 2011 and annual information form dated July 31, 2008,
may cause our actual results, level of activity, performance or achievements to
differ materially from those implied by forward looking statements. Readers are
cautioned not to place undue reliance on these forward-looking statements, which
are made only as of the date of this press release. Pacgen disclaims any
intention or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise, except as
required by law. For all forward-looking statements, Pacgen claims the safe
harbour for forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995.

Pacgen Life Science (TSXV:PBS)
Historical Stock Chart
From Nov 2024 to Dec 2024

Pacgen Life Science (TSXV:PBS)
Historical Stock Chart
From Dec 2023 to Dec 2024